Literature DB >> 33302747

Can accurate evaluation of the treatment success after radiofrequency ablation of liver tumors be achieved by visual inspection alone? Results of a blinded assessment with 38 interventional oncologists.

Gregor Laimer1, Peter Schullian1, Daniel Putzer1, Gernot Eberle1, S Nahum Goldberg2,3, Reto Bale1.   

Abstract

OBJECTIVES: To assess the difficulties in the immediate judgment of treatment success after radiofrequency ablation (RFA) of liver tumors by visual inspection alone and to evaluate whether radiologist's expertise affects the resultant judgment.
METHODS: Peri-interventional CT-scans of nine patients with nine hepatocellular carcinomas with known outcomes after RFA were presented to 38 participants from 14 different countries. In a total of 342 reads, all interventional oncologists assessed the pre- and immediate post-interventional CT-scans through conventional side-by-side juxtapositioning of images and judged whether complete ablation (i.e., technical success and technique efficacy) was achieved. Results were compared regarding expertise in percutaneous tumor ablation (>50 interventions performed). An 'overcall' was defined as insufficient ablation that was misjudged as sufficient, and an 'undercall' as an erroneous assessment of complete ablation.
RESULTS: Overall 3.97 ± 1.27 out of 9 (44.1%) cases per radiologist were misjudged. The mean number of overcalls and undercalls per radiologist were 0.74 ± 0.50 out of 2 (37.0%), and 3.24 ± 1.28 out of 7 (46.3%), respectively. 18/38 (47.4%) participants had considerable experience in percutaneous tumor ablation, with such expertise having no significant influence on the results (overall: p = 0.70; overcalls: p = 0.87; undercalls: p = 0.75).
CONCLUSIONS: Conventional side-by-side evaluation of treatment success after RFA of liver tumors by the juxtaposition of pre- and post-interventional CT-scans is very difficult for experienced radiologists. The implementation of advanced processing techniques such as rigid/non-rigid image fusion with the assessment of the periablational margin is thus likely needed in order to decrease errors and objectively evaluate technical success and predict technique efficacy of liver RFA.

Entities:  

Keywords:  Radiofrequency ablation; image fusion; liver; local tumor progression; periablational margin

Mesh:

Year:  2020        PMID: 33302747     DOI: 10.1080/02656736.2020.1857445

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  3 in total

1.  Study Protocol PROMETHEUS: Prospective Multicenter Study to Evaluate the Correlation Between Safety Margin and Local Recurrence After Thermal Ablation Using Image Co-registration in Patients with Hepatocellular Carcinoma.

Authors:  Timo T M Oosterveer; Gonnie C M van Erp; Pim Hendriks; Alexander Broersen; Christiaan G Overduin; Carla S P van Rijswijk; Arian R van Erkel; Rutger W van der Meer; Maarten E Tushuizen; Adriaan Moelker; Martijn R Meijerink; Otto M van Delden; Koert P de Jong; Christiaan van der Leij; Maarten L J Smits; Thijs A J Urlings; Jeffrey P B M Braak; Elma Meershoek-Klein Kranenbarg; Bianca van Duijn-de Vreugd; Evelijn Zeijdner; Jelle J Goeman; Jurgen J Fütterer; Minneke J Coenraad; Jouke Dijkstra; Mark C Burgmans
Journal:  Cardiovasc Intervent Radiol       Date:  2022-03-01       Impact factor: 2.797

2.  Feasibility and Efficacy of Fusion Imaging Systems for Immediate Post Ablation Assessment of Liver Neoplasms: Protocol for a Rapid Systematic Review.

Authors:  Pragati Rai; Sarada Dakua; Julien Abinahed; Shidin Balakrishnan
Journal:  Int J Surg Protoc       Date:  2021-09-17

3.  Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases.

Authors:  Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Mithat Gonen; Nancy E Kemeny; Carlie Sigel; Leonard B Saltz; Karen T Brown; Anne M Covey; Joseph P Erinjeri; Lynn A Brody; Etay Ziv; Hooman Yarmohammadi; Henry Kunin; Afsar Barlas; Elena N Petre; Peter T Kingham; Michael I D'Angelica; Katia Manova-Todorova; Stephen B Solomon; Constantinos T Sofocleous
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.